Updating the ethical guidance for gene and cell therapy research participation

Affiliations

¹ Center for Health Care Ethics, Saint Louis University, St. Louis, MO, USA; Chair of Castle IRB, Wildwood, MO, USA. Electronic address: stephanie.cargill@slu.edu.
² Center for Health Care Ethics, Saint Louis University, St. Louis, MO, USA.
³ Institutional Biosafety Committee (IBC), Clinical Biosafety Services, Wildwood, MO, USA.

Stephanie Solomon Cargill et al. Mol Ther. 2021.

. 2021 Aug 4;29(8):2394-2395.

doi: 10.1016/j.ymthe.2021.07.009. Epub 2021 Jul 23.

¹ Center for Health Care Ethics, Saint Louis University, St. Louis, MO, USA; Chair of Castle IRB, Wildwood, MO, USA. Electronic address: stephanie.cargill@slu.edu.
² Center for Health Care Ethics, Saint Louis University, St. Louis, MO, USA.
³ Institutional Biosafety Committee (IBC), Clinical Biosafety Services, Wildwood, MO, USA.

No abstract available

References

1. US Food and Drug Administration. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ....
1. Chapman A. Addressing the ethical challenges of first in-human trials. J. Clin. Res. Bioeth. 2011;2:1–8.
1. Anderson W.F. Human gene therapy: scientific and ethical considerations. J. Med. Philos. 1985;10:275–291. - PubMed
1. Riva L., Petrini C. A few ethical issues in translational research for gene and cell therapy. J. Transl. Med. 2019;17:395. - PMC - PubMed
1. National Academies of Sciences . National Academies Press; 2017. Engineering. Human Genome Editing: Science, Ethics, and Governance. - PubMed